Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Status and phase

Completed

Phase 2

Conditions

Chronic Obstructive Pulmonary Disease

Lung Disease

Treatments

Drug: AZD2423

Drug: AZD2423 Placebo

Study type

Interventional

Funder types

Industry

Identifiers

D3320C00001

2010-020141-26 (EudraCT Number)

Details and patient eligibility

About

The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.

Enrollment

71 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
≥ 40 years of age at Visit 1
Clinical diagnosis of COPD (GOLD stage 1)
FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)
FEV1/FVC <70% post-bronchodilator at Visit 1 (GOLD stage 1)

Exclusion criteria

Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study
A past history or current indication of renal (kidney) failure
Subjects at risk of active tuberculosis or of disease reactivation
Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)